Page D L, Dupont W D, Jensen R A
Department of Pathology, Vanderbilt University Medical School, Nashville, Tennessee 37232-2561, USA.
Cancer Epidemiol Biomarkers Prev. 1996 Jan;5(1):29-32.
Micropapillary patterns of apocrine change in human female breasts are common histological findings. They have been identified as cancer associated and implicated as an indicator of cancer risk in a predictive manner. This study has stratified papillary apocrine change (PAC) into categories of increasing complexity using a combination of cytological and histological pattern rules. Cases (2,876) were identified in a review of 10,357 benign breast biopsies. Of 5966 women, 1613 and PAC and were followed for a median of 20 years after biopsy for the development of invasive carcinoma of the breast. There was a slight association with cancer risk elevation, but most of this disappeared when women with concurrent, specifically identified patterns of atypical hyperplasia (AH) were excluded from the groups with PAC. The resultant relative risk was only 1.2 after women with AH were excluded. Only 1% of the reviewed biopsies demonstrated highly complex patterns of PAC, and 20% of these had coexistent lesions of AH. Women with highly complex patterns of PAC without AH did experience a relative risk of 2.4 (95% confidence interval = 0.77-7.04) but without statistical significance. More than one-half of all PAC patterns occurred without concurrent foci of lesions of proliferative disease that are associated with a slight elevation of breast cancer risk (at least 1.5 times); when present without proliferative disease, there was no suggestion of later breast cancer risk for PAC.
人类女性乳房顶泌汗腺化生的微乳头模式是常见的组织学表现。它们已被确定与癌症相关,并被认为是预测癌症风险的指标。本研究使用细胞学和组织学模式规则的组合,将乳头状顶泌汗腺化生(PAC)分为复杂性增加的类别。在对10357例良性乳腺活检进行回顾时,共识别出2876例病例。在5966名女性中,1613例患有PAC,并在活检后中位随访20年,观察是否发生浸润性乳腺癌。PAC与癌症风险升高存在轻微关联,但当同时患有特定非典型增生(AH)模式的女性被排除在PAC组之外时,这种关联大多消失。排除患有AH的女性后,最终相对风险仅为1.2。在回顾的活检中,只有1%显示出高度复杂的PAC模式,其中20%同时存在AH病变。没有AH的高度复杂PAC模式的女性确实经历了2.4的相对风险(95%置信区间=0.77-7.04),但无统计学意义。超过一半的PAC模式发生时,没有同时存在与乳腺癌风险轻微升高(至少1.5倍)相关的增殖性疾病病灶;当不存在增殖性疾病时,没有迹象表明PAC会增加后期患乳腺癌的风险。